PL3728289T3 - Zoptymalizowane związki - Google Patents

Zoptymalizowane związki

Info

Publication number
PL3728289T3
PL3728289T3 PL18890144.1T PL18890144T PL3728289T3 PL 3728289 T3 PL3728289 T3 PL 3728289T3 PL 18890144 T PL18890144 T PL 18890144T PL 3728289 T3 PL3728289 T3 PL 3728289T3
Authority
PL
Poland
Prior art keywords
optimised
compounds
optimised compounds
Prior art date
Application number
PL18890144.1T
Other languages
English (en)
Inventor
David Jackson
Ian Holmes
Weiguang Zeng
Christophe Demaison
Original Assignee
Axelia Oncology Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017905128A external-priority patent/AU2017905128A0/en
Application filed by Axelia Oncology Pty Ltd filed Critical Axelia Oncology Pty Ltd
Publication of PL3728289T3 publication Critical patent/PL3728289T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
PL18890144.1T 2017-12-21 2018-12-21 Zoptymalizowane związki PL3728289T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2017905128A AU2017905128A0 (en) 2017-12-21 Optimised compounds
AU2018901056A AU2018901056A0 (en) 2018-03-29 Optimised compounds (2)
AU2018903597A AU2018903597A0 (en) 2018-09-25 Optimised compounds (3)
PCT/AU2018/051397 WO2019119067A1 (en) 2017-12-21 2018-12-21 Optimised compounds

Publications (1)

Publication Number Publication Date
PL3728289T3 true PL3728289T3 (pl) 2026-01-26

Family

ID=66992416

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18890144.1T PL3728289T3 (pl) 2017-12-21 2018-12-21 Zoptymalizowane związki

Country Status (18)

Country Link
US (2) US12195557B2 (pl)
EP (1) EP3728289B1 (pl)
JP (2) JP7439367B2 (pl)
KR (1) KR102747437B1 (pl)
CN (1) CN111491943A (pl)
AU (1) AU2018391325B2 (pl)
BR (1) BR112020012360A2 (pl)
CA (1) CA3085377A1 (pl)
DK (1) DK3728289T3 (pl)
ES (1) ES3053993T3 (pl)
FI (1) FI3728289T3 (pl)
IL (1) IL275360B2 (pl)
PL (1) PL3728289T3 (pl)
PT (1) PT3728289T (pl)
RS (1) RS67510B1 (pl)
SG (1) SG11202004895UA (pl)
SI (1) SI3728289T1 (pl)
WO (1) WO2019119067A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012037612A1 (en) 2010-09-22 2012-03-29 The University Of Melbourne Novel immunostimulatory method
PL3728289T3 (pl) 2017-12-21 2026-01-26 Axelia Oncology Pty Ltd Zoptymalizowane związki
EP3727372A4 (en) * 2017-12-21 2021-10-27 Ena Therapeutics Pty Ltd ADMINISTRATION OF A TLR2 AGONIST TO TREAT OR PREVENT AN INFECTIOUS RESPIRATORY DISEASE
JP2022539091A (ja) 2019-06-26 2022-09-07 アクセリア オンコロジー ピーティーワイ リミテッド 新規な分子
AU2020343725A1 (en) * 2019-09-04 2022-03-24 Axelia Oncology Pty Ltd Cancer treatment
CN114364378A (zh) * 2019-09-04 2022-04-15 阿克塞利阿肿瘤学私人有限公司 癌症免疫疗法
EP4157255A4 (en) * 2020-05-26 2024-07-03 Ena Respiratory Pty Ltd CORONAVIRUS TREATMENT
AU2021294603A1 (en) 2020-06-26 2022-12-15 Ena Respiratory Pty Ltd Branched lipid compounds
WO2023028661A1 (en) * 2021-09-02 2023-03-09 Ena Respiratory Pty Ltd Formulation

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2311478T3 (es) 1999-11-19 2009-02-16 Csl Limited Composiciones de vacuna contra el hcv.
WO2001090129A2 (en) 2000-05-19 2001-11-29 Corixa Corporation Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-base compounds
EP1382352A1 (de) 2002-07-19 2004-01-21 GBF Gesellschaft für Biotechnologische Forschung mbH Bisacyloxypropylcystein-Konjugate und deren Verwendung
BR0313154A (pt) 2002-08-12 2005-08-02 Council The Queensland Inst Of Novos lipopeptìdeos imunogênicos que compreendem epitopos de célula t-helper e de célula b
CN101113178A (zh) 2002-08-12 2008-01-30 昆士兰医学研究所理事会 包含辅助t细胞和细胞毒性t淋巴细胞(ctl)表位的新免疫原性脂肽
EP1550458A1 (en) 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
US20060002941A1 (en) 2004-01-23 2006-01-05 Vievax Corp. Compositions comprising immune response altering agents and methods of use
WO2005079419A2 (en) 2004-02-17 2005-09-01 The Regents Of The University Of California Methods of treating immunopathological disorders
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
EP2460533A3 (en) 2004-10-18 2014-01-08 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
EP1666056A1 (en) 2004-12-06 2006-06-07 Bestewil Holding B.V. Cancer vaccine vesicles
WO2006069262A2 (en) 2004-12-21 2006-06-29 Vaxinnate Corporation Compositions of influenza viral proteins and methods of use thereof
US20100129385A1 (en) 2005-02-08 2010-05-27 Jackson David C Immunogenic molecules
JP2008531502A (ja) 2005-02-22 2008-08-14 ザ レジェンツ オブ ザ ユニバーシティ オブ カリフォルニア 胃腸の炎症を処置する方法
EP1787660A1 (en) 2005-11-22 2007-05-23 GBF Gesellschaft für Biotechnologische Forschung mbH New adjuvants on the basis of bisacyloxypropylcysteine conjugates and their uses in pharmaceutical compositions
ES2555544T3 (es) 2006-03-07 2016-01-04 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
US20080170996A1 (en) 2006-07-28 2008-07-17 The Board Of Regents Of The University Of Texas System Compositions and Methods for Stimulation of Lung Innate Immunity
AU2014202674B2 (en) 2007-05-04 2014-08-14 Marina Biotech, Inc. Amino acid lipids and uses thereof
DK2200638T3 (en) 2007-10-09 2016-06-06 Univ Melbourne Compositions for the transfection of cells
WO2009137103A2 (en) 2008-05-09 2009-11-12 Ourth Donald D Anti-cancer/anti-viral compounds and methods of use
WO2009155332A1 (en) 2008-06-17 2009-12-23 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
WO2010028246A2 (en) 2008-09-05 2010-03-11 Id Biomedical Corporation Of Quebec Novel compositions and adjuvants
WO2010093436A2 (en) 2009-02-11 2010-08-19 Carson Dennis A Toll-like receptor modulators and treatment of diseases
AU2010229835B2 (en) 2009-03-25 2015-01-15 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
JP2012523379A (ja) 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
GB0907989D0 (en) 2009-05-08 2009-06-24 Hybrid Systems Ltd Multivalent adjuvant display
EP2338521A1 (en) 2009-12-28 2011-06-29 Helmholtz-Zentrum für Infektionsforschung GmbH Lipopeptide- and lipoprotein-conjugates and its use
AU2011232421B2 (en) 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
WO2012037612A1 (en) 2010-09-22 2012-03-29 The University Of Melbourne Novel immunostimulatory method
CN113876945A (zh) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
CN105555756B (zh) 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
US20170274068A1 (en) * 2014-09-12 2017-09-28 The University Of Melbourne Immunological reagent
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
JP2016216593A (ja) 2015-05-19 2016-12-22 株式会社リコー 反応材、熱交換器及びケミカルヒートポンプ
EP4378957A3 (en) 2015-07-29 2024-08-07 Novartis AG Combination therapies comprising antibody molecules to pd-1
US11464853B2 (en) 2016-02-26 2022-10-11 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
CN118161614A (zh) * 2017-03-31 2024-06-11 艾娜呼吸私人有限公司 用tlr2激动剂治疗呼吸道感染
NL2018803B1 (en) 2017-04-27 2018-11-05 Academisch Ziekenhuis Leiden Handelend Onder De Naam Leids Univ Medisch Centrum/ H O D N Lumc Adjuvant compounds
EA202090319A1 (ru) 2017-08-30 2020-10-16 Окленд Юнисервисиз Лимитед Пептидные конъюгаты, способ конъюгации и их использование
PL3728289T3 (pl) 2017-12-21 2026-01-26 Axelia Oncology Pty Ltd Zoptymalizowane związki
EP3727372A4 (en) 2017-12-21 2021-10-27 Ena Therapeutics Pty Ltd ADMINISTRATION OF A TLR2 AGONIST TO TREAT OR PREVENT AN INFECTIOUS RESPIRATORY DISEASE
JP2022539091A (ja) 2019-06-26 2022-09-07 アクセリア オンコロジー ピーティーワイ リミテッド 新規な分子
AU2020343725A1 (en) 2019-09-04 2022-03-24 Axelia Oncology Pty Ltd Cancer treatment
CN114364378A (zh) 2019-09-04 2022-04-15 阿克塞利阿肿瘤学私人有限公司 癌症免疫疗法
EP4157255A4 (en) 2020-05-26 2024-07-03 Ena Respiratory Pty Ltd CORONAVIRUS TREATMENT
AU2021294603A1 (en) 2020-06-26 2022-12-15 Ena Respiratory Pty Ltd Branched lipid compounds

Also Published As

Publication number Publication date
FI3728289T3 (fi) 2025-11-11
JP2024001114A (ja) 2024-01-09
IL275360A (en) 2020-07-30
KR102747437B1 (ko) 2024-12-26
CN111491943A (zh) 2020-08-04
BR112020012360A2 (pt) 2020-11-24
SI3728289T1 (sl) 2026-01-30
PT3728289T (pt) 2025-11-28
ES3053993T3 (en) 2026-01-28
AU2018391325B2 (en) 2024-07-11
EP3728289A4 (en) 2021-10-13
IL275360B1 (en) 2023-06-01
AU2018391325A1 (en) 2020-06-18
US12195557B2 (en) 2025-01-14
IL275360B2 (en) 2023-10-01
US20250066416A1 (en) 2025-02-27
JP2021506915A (ja) 2021-02-22
KR20200101428A (ko) 2020-08-27
SG11202004895UA (en) 2020-06-29
RS67510B1 (sr) 2025-12-31
DK3728289T3 (da) 2025-11-24
EP3728289B1 (en) 2025-09-10
EP3728289A1 (en) 2020-10-28
US20210230217A1 (en) 2021-07-29
WO2019119067A1 (en) 2019-06-27
CA3085377A1 (en) 2019-06-27
JP7439367B2 (ja) 2024-02-28

Similar Documents

Publication Publication Date Title
IL275505A (en) Diazindole compounds
GB201708456D0 (en) Senolytic compounds
GB201700814D0 (en) Compounds
GB201704327D0 (en) Compounds
IL275360A (en) Optimal compounds
GB201704325D0 (en) Compounds
SMT202200100T1 (it) Composti di fenil-2-idrossi-acetilammino-2-metil-fenile
GB201713962D0 (en) Compounds
IL292485B1 (en) Pyridylpyridone compounds
IL272815B (en) Morpholinylpyridone compounds
GB201707938D0 (en) Compounds
GB201707856D0 (en) Compounds
GB201706162D0 (en) Compounds
GB201702221D0 (en) Compounds
GB201716369D0 (en) Compounds
GB201721751D0 (en) Compounds
GB201707852D0 (en) Compounds
GB201703282D0 (en) Compounds
AU2017905128A0 (en) Optimised compounds
GB201721758D0 (en) Compounds
GB201721754D0 (en) Compounds
GB201721665D0 (en) Compounds
GB201720495D0 (en) ß-lactone compounds
GB201716688D0 (en) Compounds
GB201716374D0 (en) Compounds